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Abstract:  
 
Isocarbacyclin is a valuable synthetic analogue of prostacyclin with potential neuroprotective 
effects for the treatment of ischemic stroke. Herein, we describe the synthesis of isocarbacyclin 
and bicyclic analogues in only 7–10 steps, with the ω-side chain diversified at a late stage. A 
combination of new reaction design, function-oriented synthesis, and late-stage diversification 
led to a series of compounds that were tested for their neuroprotective activities. Efforts toward 
the synthesis of tricyclic analogues of isocarbacyclin, using the same combination of metal-
catalyzed reactions, is also described. 
 
 
 
Keywords: Isocarbacyclin | Synthesis | Analogues | Neuroprotective | Stroke 
 
Article:  
 
1. Introduction 
 
 The last century has experienced the development of many synthetic strategies and 
syntheses of medicinal leads.1 Total syntheses of complex small molecules, including natural 
products and synthetic variants, exhibit almost infinite variations as they can afford unique 
approaches and disconnections. Each target presents a puzzle that requires scientists to solve 
challenges to their structures for which solutions may not be available using known synthetic 
methods. Thus, the design and development of new reactions has a powerful influence on the 
pathways that can be imagined to construct molecules. 
 One of the challenges in total synthesis is the number of steps required to synthesize a 
target molecule. Increasing the number of steps has a negative influence on the required time, 
cost and waste.2, 3 Improvements in the step-economy of a synthetic plan is possible by 
utilization of a few key strategies: 1) new reaction design; 2) function-oriented synthesis; 3) 
semi-synthesis; and 4) late-stage diversification.2, 3, 4 The first three strategies shorten the number 
of steps to a single compound, and the last method shortens the total number of steps to more 
than one compound by judiciously choosing a diversification point that has the highest molecular 
complexity while still allowing for the desired modifications. As will be illustrated herein, these 
different strategies are not mutually exclusive so more than one of these can be used to greatly 
shorten the total number of steps in a synthetic project. 
 Isocarbacyclin, first synthesized in the 1980′s,5 is a stable synthetic analogue of 
prostacyclin (1, Fig. 1).6 Prostacyclin (1) is a highly potent vasodilator and inhibitor of platelet 
aggregation, however; it is inherently unstable due to the vinyl ether moiety in its structure. This 
instability limits its use in clinical applications.7, 8, 9, 10 Isocarbacyclin (2) and clinprost (3) were 
developed and found to be more stable than prostacyclin (1, Fig. 1).6, 11, 12, 13 
 In addition to vasodilation, both isocarbacyclin (2) and clinprost (3) were reported to be 
highly potent neuroprotective agents for the treatment of ischemic stroke.11, 13-17 Stroke is one of 
the leading causes of death and has been known to cause serious injuries to many people.18 
Between the two types of stroke, hemorrhagic and ischemic, ischemic stroke accounts for the 
majority of incidents with about 87% of strokes being ischemic.19, 20 Despite decades of research, 
treatment options for ischemic stroke remain limited. Currently the only FDA-approved therapy 
is tissue-plasminogen activator (tPA), which has a limited time window.17, 21, 22 Other medicines 
that are available in the market are only used as preventative therapies for protection against 
platelet aggregation, such as clopidogrel or against blood clotting such as warfarin.23 Therefore, 
the search for novel therapeutics that have the potential to protect brain tissue from this damage 
is urgent.21, 24 
 Isocarbacyclin (2) and clinprost (3) are promising neuroprotective agents, however, 
exploration of their biological activity has been limited as a result of the length of their 
syntheses. Both molecules were synthesized by several groups with diverse approaches, 
however, most were 20 or more steps with the shortest reported syntheses requiring 15 steps.25-37 
Isocarbacyclin (2) possesses a bicyclo[3.3.0]octene system with four contiguous stereocenters 
and two side chains; an octenol ω-side chain and an α-side chain that contains the pentanoic acid 
connected to the endocyclic alkene.4 Synthetic challenges, including the construction of the 
bicyclic ring system and regioselectivity of both the endocyclic double bond (C6-C9α) and the α-
sidechain, are some of the difficulties that must be surmounted in the synthetic approaches.38, 39 
Moreover, there is the problem of how to stereoselectively introduce the four contiguous 
stereocenters. With respect to examining analogues, it is valuable to explore variability with the 
ω-sidechain since this region of the molecule has been shown to impact activity.39 
 
 
Fig. 1. Prostacyclin (1), isocarbacyclin (2) and clinprost (3) structures 
 
 Croatt et al. reported the synthesis of clinprost (3) in only 9 total steps utilizing 
inexpensive and commercially available starting materials.4, 40 This synthetic route was used, 
with several optimizations presented herein, to synthesize isocarbacyclin (2) and new bicyclic 
analogues in which the ω-side chain was diversified at a late stage in the synthesis using different 
alkenes. Moreover, efforts toward the synthesis of tricyclic analogues will be described herein by 
a different synthetic approach using the same metal-catalyzed key reactions used in the synthesis 
of isocarbacyclin. 
 
2. Results and discussion 
 
2.1 Synthesis of isocarbacyclin and its bicuclic analogues 
 
 The step-economical synthesis of clinprost (3) reported by the Croatt Group was further 
optimized to make isocarbacyclin’s bicyclic building block (11, Scheme 1), which was made in 
only 6 steps from commercially available materials.40 This route was designed to enable late-
stage diversification by using a cross-metathesis reaction of different commercially available 
alkenes to afford isocarbacyclin and different analogues. The synthesis of the core begins by 
reacting excess pimelic acid (4) with bis-allylic alcohol (5) to generate monoester 6 as a major 
product, followed by an aldol condensation with acrolein. A limitation of the second step was the 
quick polymerization of acrolein during the reaction workup and purification. Acidic workup 
was highly beneficial for enabling solvation of the acrolein polymers. Various conditions were 
screened to find that using LiHMDS as a base in THF gave yields that ranged widely, from 53% 
to less than 15%. Later, we found that using solid LiHMDS increased the yield up to 72% with 
good reproducibility. Another important aspect of this reaction was the addition of the lithium 
enolate to a solution of acrolein, instead of adding acrolein to the enolate. 
 
 
Scheme 1. Synthesis of the bicyclic building block (11) 
 The resulting acid (7) was subjected to methylation and dehydration to generate ester 9 in 
a 1:1 ratio of E:Z isomers, which was reacted with Pd0 to accomplish an allylic rearrangement 
and decarboxylation to form tetraene 10. This new type of decarboxylation has been studied in 
more detail by the Croatt Group.41 Tetraene (10) is then reacted with a RhI catalyst under an 
atmosphere of carbon monoxide in a bis-diene [2 + 2 + 1] cycloaddition reaction followed by an 
in situ reduction. The four stereocenters of bicycle 11 are installed with the same relative 
configuration as in isocarbacyclin (2). The yield is low as only the Z-isomer reacts to give 
bicycle 11 while the E-isomer remains unchanged. Moreover, the intermediate ketone isomerizes 
over time or under more forcing conditions to the more stable and undesired isomer (Scheme S1, 
Supplementary Material). Different conditions were screened in order to more efficiently form 
the desired product, and the optimal conditions were found to run the reaction for 8–10 h at 70 °C 
(22% yield over 2 steps; Table S1, Supplementary Material). The yield for this step led us to 
design a route for a different type of analogues, tricyclic, where the double bond in the tetraene 
derivative is locked in the Z-form only, vide infra. 
 To complete the synthesis of isocarbacyclin (2), a RuII-catalyzed cross-metathesis 
reaction was utilized to attach the ω-side chain. The parent side chain, (S)-3-acetoxy-oct-1-ene 
(12), was synthesized using an enzymatic resolution of racemic 1-octen-3-ol.42 The cross-
metathesis reaction yielded a mixture of enantiomerically enriched diastereomers since the 
bicyclic core was racemic and the side chain was enantioenriched. The diastereomeric mixture of 
13 and dia-13 was separated using standard silica gel chromatography. Hydrolysis of the methyl 
ester and acetate protecting group using NaOH generates isocarbacyclin (2) and its diastereomer 
(14), each in an enantioselective fashion (Scheme 2). 
 
 
Scheme 2. Enantioselective synthesis of isocarbacyclin (2) and its diastereomer (14). 
 
 With the completed bicyclic core (11) in hand, a cross-metathesis approach to analogues 
was utilized using three different available terminal alkenes, followed by hydrolysis of the 
methyl ester (Scheme 3). Additionally, the bicyclic core without a side chain (11) was directly 
subjected to hydrolysis. Cross-metathesis reactions with p-styrene and myrcene were attempted, 
but only homocoupling byproducts were observed. 
 
 
 
Scheme 3. Successful synthesis of analogues of isocarbacyclin. 
 
2.2 Efforts toward the synthesis of tricuclic isocarbacyclin analogues 
 
 During the synthesis of isocarbacyclin (2) and its analogues, one focus was on optimizing 
the bis-diene [2 + 2 + 1] cycloaddition of tetraene 10 that yielded the bicyclic building block (19) 
for future analogues. We were able to increase the yield to 22%, but were not able to improve the 
yield further due to limitations related to the E-isomer being unreactive (Scheme 4A). This issue 
led us to design a new analogue whereby the bis-diene is locked as the Z-isomer to generate a 
tricyclic core (20) for new types of isocarbacyclin analogues (Scheme 4B). Importantly, the 
tricyclic analogues position the α-side chain in a manner similar to prostacyclin (1). Further 
validation of this type of analogue is the fact that prostacyclin has tricyclic analogues that are 
currently in clinical use as vasodilators including beraprost and treprostinil.43 
 
 
Scheme 4. Bicyclic (19) versus tricyclic (20) building blocks. 
 
 A model system for the tricyclic analogues was first developed to test if the Pd-catalyzed 
decarboxylation and Rh-catalyzed cycloaddition reactions would be successful (Scheme 5). The 
model system synthesis starts from commercially available β-ketoester 21 that is converted to 
mesylate 22 using MsCl and Et3N. Mesylate 22 was found to be unstable and taken directly to 
the Stille coupling without further purification to afford dienoic ester 23. 
 
 
 
Scheme 5. Synthesis of the tricyclic core (26) in the model system. 
 
 Different conditions were screened to optimize the Stille coupling reaction (Table S2, 
Supplementary Material), to find that running the reaction at 90 °C in a microwave produces a 
60% yield. The resulting ester (23) from the Stille coupling was then subjected to hydrolysis with 
LiOH to afford dienoic acid 24. Although a one-flask reaction for Stille coupling and hydrolysis 
was successful to yield dienoic acid 24, sufficient purification of this compound was problematic 
due to streaking of the stannane byproducts. Gratifyingly, dienoic acid 24 underwent an 
intermolecular decarboxylative coupling with bis-allylic alcohol (5) when subjected to Pd0 
conditions. The decarboxylated product (25) was subjected to RhI catalysis under a carbon 
monoxide atmosphere with several conditions to yield traces of tricycle 26 (Table S3, 
Supplementary Material). Tricycle 26 was not fully characterized due to the volatility of the 
starting material and the isomerization of the product, however, it was clear that both reactions, 
decarboxylation and cycloaddition, were successful which validated moving from the model 
system to the actual synthetic route of the tricyclic analogue. 
 Based on the results of the model system, a similar synthetic scheme for the tricyclic core 
(20) was developed, starting with cyclopentanone (27). Reaction with t-butyl bromoacetate (28) 
produced ketone 29 (Scheme 6), which was then reacted with methyl chloroformate, using 
LiHMDS as a base, to provide diester 30. It was found that allowing the methylcarboxylation 
reaction to warm to room temperature for more than four hours resulted in significant 
decomposition. As a result, the reaction was left in the cooling bath for four hours to optimally 
synthesize the diester (30). 
 
 
Scheme 6. Synthesis of tetraene building block (34) for the tricyclic isocarbacyclin analogue. 
 Diester 30 was expected to act similarly in the mesylation as in the model system. 
Unfortunately, an unknown byproduct formed in addition to the desired mesylate (31) when 
similar conditions were used. Different conditions were screened to form the mesylate, bromide 
or triflate derivatives (Table S4, Supplementary Material), but all trials either resulted in a 
byproduct along with the product in the case of the mesylate and the bromide or no reaction in 
the case of the triflate. Although not ideal, the unoptimized crude mesylate product was 
successfully subjected to Pd0 catalysis for the Stille coupling to generate dienoic ester 32 in a 
20% yield over the two steps. Dienoic ester 32 underwent chemoselective hydrolysis of the 
methyl ester to afford dienoic acid 33. The intermolecular decarboxylative coupling reaction 
with divinylcarbinol was again successful, which yielded the requisite tetraene 34 to generate 
tricyclic isocarbacyclin analogues. 
 Tetraene 34 was expected to react in the bis-diene [2 + 2 + 1] reaction similar to the 
model system and isocarbacyclin synthesis. However, it did not react when subjected to 
[RhCl(CO)2]2 under carbon monoxide atmosphere at 80 °C. Using more forcing conditions by 
the addition of AgSbF6 to generate a cationic rhodium catalyst, a cyclization reaction occurred 
with the pendant ester to generate lactone 35 (Scheme 7). Under a variety of solvents, catalysts, 
temperatures, and additives, tricycle 20 was never observed. The mechanism for the process to 
form lactone is still under investigation but the lack of formation of tricycle 20 requires a 
reanalysis of the synthetic approach. 
 
 
Scheme 7. Cyclization of bis-diene 34 to afford bicycle 35. 
 
2.3. Biological evaluation of isocarbacyclin and its bicyclic analogues 
 
 Isocarbacyclin and bicyclic analogues (2, 15–18) were tested in vitro for neuroprotection 
using embryonic mouse cortical neurons. The use of primary cultures more closely approximate 
normal neurons than is possible using cell lines. It has previously been shown that isocarbacyclin 
derivatives bind to and protect certain areas of the brain, with the cortex being one of the areas 
protected under ischemic conditions.44 Two separate assays were run, one examining 
neuroprotection from glucose deprivation, and a second one where the cells were deprived of 
both glucose and oxygen. The second condition is a more severe stress, which more closely 
mimics ischemia and reperfusion. Unfortunately, the compounds showed neuronal cell toxicity 
in the assays with minimal, if any, neuroprotection observed. 
 
3. Conclusion 
 
 The enantioselective total synthesis of isocarbacyclin was described herein using only 9 
steps from inexpensive and commercially available materials. Three metal-catalyzed reactions, 
including Pd0-catalyzed decarboxylation, RhI-catalyzed cycloaddition and RuII-catalyzed cross 
metathesis reactions, were utilized in this synthesis. Other analogues were synthesized by 
attaching different ω-side chains in a late-stage to shorten the synthesis to 7–10 steps. Another 
generation of isocarbacyclin analogues was developed to increase the yield of the cycloaddition 
step compared to isocarbacyclin synthesis and to mimic the structure of the endogenous analogue 
prostacyclin. A model system worked successfully for the Pd0-catalyzed decarboxylation and 
RhI-catalyzed bis-diene [2 + 2 + 1] cycloaddition reactions that were used in the synthesis of 
isocarbacyclin. However, ester substitution of the cyclopentane ring resulted in an unexpected 
lactonization reaction. For future analogues of this type, the carboxyl group will be revealed at a 
late stage in the synthesis. Isocarbacyclin and its bicyclic analogues were tested in vitro against 
ischemic stroke, and a detrimental level of toxicity was observed. 
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